NUVB — Nuvation Bio Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1811063 ·
Last close
$3.90
Market Cap
$1.37B
52W High
$9.75
52W Low
$3.79
ADV30
5,229,568
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 44,951,000 | 33,022,000 | -42,210,000 | -41,899,000 | 778,392,000 | 153,766,000 | 550,417,000 |
| Jun 2026 | 31,687,000 | 22,216,000 | -51,036,000 | -62,840,000 | 744,503,000 | 258,604,000 | 490,639,000 |
| Mar 2026 | 83,228,000 | 77,237,000 | 3,881,000 | 5,397,000 | 610,241,000 | 125,391,000 | 290,677,000 |
| Dec 2025 | 41,865,000 | 40,586,000 | -34,037,000 | -36,592,000 | 594,822,000 | 164,086,000 | 289,106,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-106,194,000
Investing CF
$-59,906,000
Financing CF
$221,801,000
CapEx
$-1,979,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.40
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,214,712,000
Inventory
$15,337,000
Receivables
$40,221,000
ST Investments
$509,604,000
EBIT TTM
$-109,678,000
Pretax Income TTM
$-135,934,000
Interest Exp TTM
$26,256,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$201,731,008
EBITDA
$-121,213,000
Free Cash Flow
$-76,062,248
Enterprise Value
$1,273,308,416
Total Cash
$663,369,984
Total Debt
$468,124,992
Shares Out
352,017,638
Trailing EPS
$-0.39
Book Value
$0.65
ROE
-49.1%
ROA
-11.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,902,000 | -213,064,000 | -204,627,000 | 594,822,000 | 289,106,000 | 305,716,000 | -173,427,000 |
| Dec 2024 | 7,873,000 | -167,557,000 | -567,939,000 | 540,626,000 | 76,838,000 | 463,788,000 | -130,413,000 |
| Dec 2023 | 0 | -99,822,000 | -75,802,000 | 621,484,000 | 16,362,000 | 605,122,000 | -67,999,000 |
| Dec 2022 | 0 | -119,734,000 | -104,199,000 | 672,141,000 | 17,065,000 | 655,076,000 | -96,108,000 |
TTM Snapshot
Revenues TTM
$169,900,000
NetIncome TTM
$-149,827,000
OpCashFlow TTM
—
Assets (Latest)
$744,503,000
Forward EPS
$-0.01
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $3.78 · call volume: 57 · put volume: 544
Expected Move to 2026-12-18:
±$1.29
(34.13%) —
implied range
$2.49 –
$5.07
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANAB | ANAPTYSBIO, INC | $1.36B | $45.61 | — |
| TYRA | Tyra Biosciences, Inc. | $1.35B | $19.57 | — |
| NBTX | Nanobiotix S.A. | $1.39B | $27.45 | — |
| DMRA | Damora Therapeutics, Inc. | $1.40B | $22.56 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.41B | $23.76 | — |
News headlines (Yahoo Finance, 1h cache)
Nuvation Bio (NUVB) On Safusidenib Data And Why The Undervaluation Narrative Persists
2026-11-19 01:15 · Yahoo
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
2026-11-16 13:00 · Yahoo
Nuvation Bio And 2 More Penny Stocks To Watch
2026-11-11 09:13 · Yahoo
Nuvation Bio (NUVB) Stock Trades Below Fair Value After Its 211% Run
2026-11-10 23:21 · Yahoo
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London
2026-11-10 21:05 · Yahoo
What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call
2026-11-08 16:14 · Yahoo
Nuvation Bio (NUVB) Q3 2026 Earnings Call Transcript
2026-11-05 15:13 · Yahoo
Nuvation Bio Inc (NUVB) Q3 2026 Earnings Call Highlights: IBTROZI Revenue Climbs 18% as ...
2026-11-05 09:12 · Yahoo
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 21:50 · Yahoo
Top 3 Penny Stocks To Watch In November 2026
2026-11-03 14:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.